Investor Relations
Jul 16, 2018
OPKO Partner Vifor Fresenius Receives Marketing Approval for RAYALDEE in Canada MORE >>
Jun 11, 2018
OPKO Health Completes Enrollment in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes and Obesity MORE >>
May 18, 2018
OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test MORE >>
May 08, 2018
OPKO Health Reports First Quarter 2018 Financial Results MORE >>

Press Releases

All Releases
OPKO's GeneDx to Showcase Leadership in Genetic Testing at the National Society of Genetic Counselors and the American Society of Human Genetics Annual Meetings
Sep 12, 2017
Demonstrates Commitment to Scientific and Clinical Advancement with More Than 35 Poster and Podium Presentations
OPKO Health to Present at Upcoming September Conferences
Aug 31, 2017
MIAMI , Aug. 31, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) ("OPKO" or "the Company"), announces that management will present a corporate update, which will include an update on its hGH development program, at the following upcoming September 2017 investor conferences: 2017 Wells Fargo
OPKO Health Reports Second Quarter 2017 Business and Financial Results
Aug 08, 2017
Conference call begins at 4:30 p.m. Eastern time today
OPKO Health to Announce 2017 Second Quarter Financial Results on August 8, 2017
Aug 03, 2017
MIAMI , Aug. 03, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the three months and six months ended June 30, 2017 , after the close of the U.S.
OPKO Health Announces KDIGO Clinical Practice Guideline Update on CKD-MBD
Jun 22, 2017
Updated Guideline Highlights the Limitations of Current Treatments for Secondary Hyperparathyroidism in Patients with Stage 3 or 4 Chronic Kidney Disease and Acknowledges Rayaldee as a Novel Vitamin D Prohormone
OPKO Provides Update to Topline Data of Phase 3 Clinical Study of hGH-CTP in Growth Hormone Deficient Adults
Jun 15, 2017
MIAMI , June 15, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announces an update to the topline data analysis of the Phase 3, double-blind, placebo-controlled study of its investigational long-acting human growth hormone product (hGH-CTP) in adults with growth hormone deficiency (GHD).
OPKO'S GeneDx Extends Relationship with University of California Health for Genetic and Molecular Testing
Jun 07, 2017
OPKO Helps Expand UC Health's leadership at the forefront of precision medicine
OPKO Health Provides Commercial Update for RAYALDEE
Jun 05, 2017
Approximately 68% of all insured lives now have access to RAYALDEE On track to reach 75% of insured lives by year end Increase to 70 field based nephrology sales representatives underway MIAMI , June 05, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announces it has entered into
OPKO Health's 4Kscore® Test Highlighted in Podium Presentation at 112th American Urological Association Annual Meeting
May 18, 2017
Prospective study conducted at Veteran Affairs hospitals confirms 4Kscore accurately predicts aggressive prostate cancer
OPKO Announces Multiple Presentations at the 112th American Urological Association Annual Meeting 
May 15, 2017
Highlights 4Kscore's ability to predict aggressive prostate cancer Showcasing 4Kscore and Claros 1 Point-of-Care System at Exhibit Booth #904 MIAMI , May 15, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq:OPK) announces that multiple podium and poster presentations highlighting the Company's
CORRECTION -- OPKO Health Inc.
May 09, 2017
MIAMI , May 09, 2017 (GLOBE NEWSWIRE) -- In a release issued earlier today by OPKO Health, Inc. (NASDAQ:OPK), please note that the headline should read "OPKO Health Reports 2017 Financial and Operating Results" rather than "OPKO Health Reports 2016 Financial and Operating Results" as originally
OPKO Health Reports 2016 Financial and Operating Results
May 09, 2017
U.S. commercial launch of RAYALDEE underway 4Kscore test utilization continues to grow; Level 1 CPT code and CMS pricing in place Pediatric global phase 3 initiated and Japanese registration trial for hGH-CTP commencing shortly Adult study trial data analysis near completion; preparation for
OPKO Health to Announce 2017 First Quarter Financial Results on May 9, 2017
May 08, 2017
MIAMI , May 08, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK), a multinational biopharmaceutical and diagnostics company, will announce operating and financial results for the three months ended March 31, 2017 , after the close of the U.S. financial markets on Tuesday, May 9, 2017 .
OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder
Mar 22, 2017
MIAMI , March 22, 2017 (GLOBE NEWSWIRE) -- OPKO Pharmaceuticals LLC , a subsidiary of OPKO Health, Inc. (NASDAQ:OPK) announces that the Company has received orphan drug designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development for OPKO's
OPKO Health's GeneDx to have Significant Presence at ACMG 2017
Mar 14, 2017
Launching New Genetic Tests in Multiple Indications Multiple Poster and Platform Presentations Highlight GeneDx' Broad Offerings in a Variety of Genetic Specialties MIAMI , March 14, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK)   announces that GeneDx, a subsidiary of OPKO Health , will
OPKO Health to Participate in the Barclays Global Healthcare Conference
Mar 14, 2017
MIAMI , March 14, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) today announces that senior management will participate at the Barclays Global Healthcare Conference taking place March 14-16, 2017 at Loew's Miami Beach Hotel .  Company management will deliver a corporate overview on
OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder 
Mar 08, 2017
MIAMI , March 08, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) through its subsidiaries, Eirgen Pharma Limited , Ireland and OPKO Pharmaceuticals LLC , has received notification from the European Commission designating OPKO's oligonucleotide-based AntagoNAT (CUR-1916) an orphan medicinal
OPKO Subsidiary GenPath Women's Health Announces the Availability of ClariTest™
Mar 07, 2017
Non-invasive prenatal test that harnesses the power of massively parallel sequencing to screen for fetal chromosomal abnormalities
OPKO Health Appoints Dr. Akhtar Ashfaq as Renal Division Senior Vice President, Clinical Research and Development
Mar 03, 2017
MIAMI , March 03, 2017 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) announced the appointment of Akhtar Ashfaq , MD, FACP, FASN to the position of Senior Vice President, Clinical Research and Development of OPKO Health's Renal Division, effective immediately.  In this role, Dr.
OPKO Health Reports 2016 Financial and Operating Results
Mar 01, 2017
Consolidated revenue for the year ended December 31, 2016 increased to $1,221.7 million from $491.7 million for the comparable period of 2015. Consolidated revenue of  $275.5 million for the three months ended December 31, 2016 was consistent with the comparable period of 2015 which was $276.2
Displaying 21 - 40 of 355